KIAA0319通过PMM2调节调节阿尔茨海默病风险:综合pQTL介导和转录基因分析的证据
Peng Wen1, Chong Han2, Hongxin Zhao3
1Department of Neurosurgery, The Third Affiliated Hospital of Zunyi Medical University, The First People's Hospital of Zunyi, Zunyi, China.
Journal of Alzheimer's disease reports
|October 2, 2025
概括
这项研究揭示了一种新的蛋白质通路,KIAA0319-PMM2,与阿尔茨海默病 (AD) 风险有关. 了解这种途径为AD提供了潜在的新治疗点.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 蛋白质组学是指蛋白质组学.
背景情况:
- 全基因组研究确定了阿尔茨海默病 (AD) 风险基因,但因果蛋白相互作用仍然不清楚.
- 了解蛋白质介导的途径对于阐明AD的发病过程至关重要.
研究的目的:
- 调查血蛋白和AD风险之间的因果关系.
- 为了确定参与AD病变发生的蛋白质介导调节通路.
主要方法:
- 利用了来自英国生物银行制药蛋白质学项目和deCODE遗传学的蛋白质定量特征位点 (pQTL) 数据.
- 应用了两个样本和两个步骤的门德尔随机化 (MR) 与调解分析.
- 整合全基因组关联研究 (GWAS) 和分析AD脑组织转录组学.
主要成果:
- 确定了7种上游蛋白质与6种下游蛋白质因果相关,影响AD风险.
- 在AD患者中发现了KIAA0319的显著下调.
- 调解分析表明,通过PMM2.2,减少KIAA0319表达增加了AD风险.
结论:
- 发现了一种新的KIAA0319-PMM2调节轴,与AD病原发生有关.
- KIAA0319和PMM2是阿尔茨海默病干预措施的潜在治疗点.
更多相关视频
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
1.2K
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.7K
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824